Wire · opportunities
QurAlis gets FDA clearance for pivotal ALS trial after encouraging Phase I/II results
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
QurAlis received FDA clearance to initiate a pivotal trial for QRL-201, an antisense oligonucleotide targeting STMN2 to treat ALS, following Phase I/II results showing a 50% reduction in functional decline in one dose group. The company plans to start the CONQUR study in the first half of 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 16 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You can now accelerate your ALS therapy development targeting STMN2 with a clear FDA path set by QurAlis' clinical progress. This opens a window to compete or partner ahead of pivotal trial launches in neurodegenerative disease.
◆ Coverage
3 sources · first reported 16 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics